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Background: Ovarian cancer is the fifth most common cause of cancer death for women in the UK. Up to 18% of cases can be attributed to germline mutations in BRCA1 and BRCA2 genes. Identifying patients who carry a BRCA mutation provides important information about potential response to treatment and eligibility for therapies such as PARP-inhibitors.
Implementation of systematic genetic testing of ovarian cancer patients via oncology clinics (mainstreamed genetic testing, MGT) is increasing.
Methods and results: This service evaluation reports on the first year of MGT at a tertiary oncology centre in London, UK. In total, 122 patients with high grade non-mucinous ovarian cancer underwent BRCA germline testing via MGT. Eighteen patients (14.8%) were found to carry a deleterious BRCA1/2 mutation. Four BRCA carriers did not meet previous criteria for genetic testing and would have been missed. Six BRCA carriers accessed PARP-inhibitors post-MGT. Only 22% of patients with a VUS were referred to clinical genetics services.
Conclusions: MGT appears to be a feasible way of providing BRCA testing to ovarian cancer patients. Greater clarity of how oncologists use VUS results is needed, as well as further research on psychosocial implications of MGT for ovarian cancer patients which may include somatic testing in the future. funding for BRCA germline testing provided by The UCLH Charity for an initial period of 12 months.
The objective of this evaluation was to examine clinical outcomes from the first year of MGT which could be used to inform development of this service.
Methods:
A service evaluation was approved by the UCLH Applied Health Research in Governance
Group.
All women with a diagnosis of high grade non-mucinous EOC currently under the care of Clinical files were reviewed for all patients who had MGT, including genetic reports. If histopathology was unclear from medical records, these were reviewed with an expert gynaecology oncology pathologist. Two local clinical genetics services were contacted to review referral patterns, family history data and referral of at-risk relatives for predictive testing.
Results:
Patient characteristics:
Between February 2015 and April 2016, 122 eligible patients had BRCA testing via MGT.
Most (100/122, 82%) had high grade serous ovarian cancer, and were diagnosed with stage III or IV disease (95/122, 78%). The median age at diagnosis was 62 years (range 28-88);
68 women (56%) were younger than 60 years at diagnosis.
BRCA mutation carriers:
mutations. Ashkenazi Jewish/Polish founder mutations comprised 11% of pathogenic mutations (2/18). Nine VUS were identified.
The prevalence of BRCA mutations in our cohort was 14.8% which is similar to other studies of large cohorts of women with EOC. 3 Two UK sites offering systematic BRCA testing to ovarian cancer patients reported a prevalence of 7.8% and 15.9% (Table 1) . 
Testing process and timing:
All BRCA germline testing was performed by the NE Thames Regional Genetics Laboratories. Median time from sample receipt to result was 26 working days (range 14-48 days).
Timing of testing ranged from at diagnosis to up to 104 months post-diagnosis.
Approximately half of patients in this cohort had been newly diagnosed within the previous 12 months (56/122, 46%). From this group, 20/56 (36%) women underwent MGT within one month of diagnosis. Amongst 18 women carrying a BRCA mutation, ten (56%) were newly diagnosed with ovarian cancer in the 12 months prior to genetic testing, six of whom were tested within one month of diagnosis. Eight carriers (44%) were diagnosed 21-104 months prior to BRCA testing.
Clinical genetics and family history:
After MGT, women with a BRCA mutation or VUS should have been referred to their local clinical genetics service by their oncologist. Most patients were referred between 12 and 43 working days after their MGT results were reported. at the time of this evaluation, 22% (4/18) of BRCA mutation carriers had not yet been referred to clinical genetics. Two of these patients were subsequently referred, 98 and 127 working days from date of MGT results. Of nine patients with a BRCA VUS, only two had been referred to clinical genetics.
Family history data documented at the time of genetic counselling was available for 13 BRCA carriers. Nine patients had a family history of breast, ovarian and/or other cancers; four patients had no significant family history and did not meet previous criteria for BRCA genetic testing (i.e. Manchester score <15).
12 Fifteen relatives of BRCA carriers were referred to clinical genetics services, with 11 undergoing predictive testing.
Patient management BRCA carriers:
Of the 18 BRCA mutation carriers, there was no change to treatment for 67% (11/18); seven patients completed first line chemotherapy with three of these patients on maintenance bevacizumab, and four completed or were undergoing second line chemotherapy. One patient was deceased eight months after MGT. Thirty-three percent (6/18) of patients were subsequently able to access PARP-inhibitors. Four patients commenced olaparib, one patient accessed rucaparib via a compassionate use programme, and one patient was participating in an olaparib clinical trial. Family history data were available for five patients in this group, and of these three did not meet previous criteria for BRCA genetic testing.
Discussion:
The MGT service at UCLH provided BRCA germline testing to 122 ovarian cancer patients and identified 18 women with BRCA mutations (prevalence 14.8%). The variation in mutation rates between the three UK sites with published BRCA testing data may be due to several factors. The lower rate in East Anglia (of 7.8%) could result from testing only newly diagnosed patients, and ethnicity; no Ashkenazi/Polish founder mutations were found in their cohort. The higher prevalence (15.9%) at the Royal Marsden may be due to a younger cohort; an age cut-off of <65 years was used for the first nine of 16 months of MGT. The higher prevalence at both UCLH and the Royal Marsden may be due to retrospective testing of patients several years from their initial diagnosis. This may indicate enrichment based on treatment response, i.e. increased prevalence of BRCA mutations in platinum-sensitive disease.
Currently there is no consensus as to the best time to offer BRCA testing to women with ovarian cancer, although many clinicians choose to do this early in the treatment pathway. At UCLH, germline testing of all patients more than 12 months after diagnosis identified 44% of BRCA carriers. MGT should be offered to patients regardless of time elapsed since diagnosis as results may inform not only clinical decisions but identification of at risk relatives for patients identified as mutation carriers, first degree blood relatives will have a 50% risk of carrying the same mutation.
Patient management was reviewed for the 18 women identified as BRCA mutation carriers. cancer susceptibility genes using next generation sequencing panels is increasingly being offered. However there remain counselling issues; the penetrance of some of these genes is uncertain, as well as how they might influence ovarian cancer management.
Currently UK clinical genetics services are commissioned to provide BRCA germline testing in individuals with a pre-test BRCA1/2 carrier probability of 10% or more as recommended in NICE guidance. 8, 17 This includes all women with high grade non-mucinous EOC. Tumour BRCA testing is available in Europe, but is not offered routinely in the UK. Within this cohort of MGT patients, two with a normal BRCA germline result were later found to carry somatic BRCA mutations. It is estimated 5-7% of women with high grade serous ovarian cancer who do not carry a BRCA germline mutation are found to have a somatic BRCA mutation. 18 These patients would be eligible for olaparib therapy or other PARP-inhibitor clinical trials, calling for greater access to tumour testing in ovarian cancer.
This evaluation demonstrates that MGT is a feasible way of providing BRCA testing to ovarian cancer patients and led to 33% of mutation carriers accessing targeted therapies.
Greater clarity of how oncologists use VUS results is needed, as is ensuring these are 
